SubHero Banner

Opdivo® (nivolumab) – Indication withdrawal

December 29, 2020 - Bristol Myers Squibb announced that in consultation with the FDA, they have decided to voluntarily withdraw the indication for Opdivo (nivolumab), for the treatment of patients with metastatic small cell lung cancer (SCLC) with progression after platinum-based chemotherapy and at least one other line of therapy.

Download PDF